BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 2 filers reported holding BRIDGEBIO PHARMA INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,058,123 | +73.0% | 40,126 | +12.9% | 0.02% | +100.0% |
Q2 2023 | $611,563 | +15.8% | 35,556 | +11.7% | 0.01% | -11.1% |
Q1 2023 | $527,907 | +112.9% | 31,840 | -2.1% | 0.01% | +80.0% |
Q4 2022 | $247,947 | -48.5% | 32,539 | -32.8% | 0.01% | -37.5% |
Q3 2022 | $481,000 | +8.6% | 48,400 | -0.7% | 0.01% | 0.0% |
Q2 2022 | $443,000 | -94.8% | 48,748 | -94.2% | 0.01% | -89.9% |
Q1 2022 | $8,578,000 | -39.2% | 845,075 | -0.0% | 0.08% | -1.2% |
Q4 2021 | $14,099,000 | -60.2% | 845,260 | +11.9% | 0.08% | -56.5% |
Q3 2021 | $35,402,000 | -23.4% | 755,322 | -0.3% | 0.18% | -18.9% |
Q2 2021 | $46,206,000 | -1.9% | 757,973 | -0.9% | 0.23% | -10.6% |
Q1 2021 | $47,110,000 | – | 764,767 | – | 0.25% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |